Market Place
Sourcing Support
Diamyd® Gets Second FDA Fast Track For Type 1 Diabetes Prevention
17 Jul 2024 //
PR NEWSWIRE
Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®
15 Feb 2024 //
PR NEWSWIRE
Diamyd Medical gains market research findings to guide U.S. commercial strategy
08 Jan 2024 //
PR NEWSWIRE
Diamyd partners with DiaUnion to recruit participants for diabetes trial
07 Nov 2023 //
PR NEWSWIRE
Diamyd Medical announces a webcast presentation on October 20
17 Oct 2023 //
PR NEWSWIRE
Diamyd partners with JDRF to advance DIAGNODE-3 Phase 3 in Type 1 Diabetes
04 Apr 2023 //
PR NEWSWIRE
Diamyd Medical brings Karin Rosén, M.D, PhD, to its Board of Directors
10 Mar 2023 //
PR NEWSWIRE
US FDA lifts partial clinical suspension on Diamyd’s diabetes therapy trial
29 Nov 2022 //
CLINICALTRIALSARENA
US Partial Clinical Hold on Diamyd® Phase III Trial Lifted by the FDA
27 Nov 2022 //
PRNEWSWIRE
Promising topline results for intralymphatic Diamyd® in patients with LADA
07 Jul 2022 //
PRNEWSWIRE
Diamyd Medical receives regulatory approvalto start Phase III trial DIAGNODE-3
21 Sep 2021 //
CISION
FDA pauses start of DIAGNODE-3 in the US pending clarification on study drug
17 Sep 2021 //
CISION
Diamyd`s rhGAD65 manufacturing facility on track for Diamyd vaccine production
31 Aug 2021 //
CISION
Diamyd Medical strengthens presence at scientific conferences
18 Aug 2021 //
CISION
Update on 24-month follow-up of Phase IIb Diamyd clinical trial
16 Jun 2021 //
CISION
DIAGNODE-2 results and meta-analysis with Diamyd®diabetes conference
26 Feb 2021 //
PRESS RELEASE
Diamyd Medical and Critical Path Institute announce data sharing collaboration
16 Dec 2020 //
PRNEWSWIRE
Analyses of prevention trials with the diabetes vaccine Diamyd®Â
01 Sep 2020 //
PRESS RELEASE
All patients have completed their 15-month visits in the European Ph IIb trial
13 Jul 2020 //
CISION
Positive Top-line Results From I/II Trial With Intralymphatic Diamyd®
20 Dec 2019 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.